I. AMENDMENT

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 14, line 3, with the following rewritten paragraph:

Co-pending applications 09/259,337 and 09/259,347, co-owned and submitted concurrently herewith, disclose binding assays which may be used to assess the percent binding affinity and immunoreactivity of conjugates after labeling if desirable. It should be stressed that, although no further purification is required after the labeling methods of the present invention, a TLC-based assay to verify the level of radioincorporation should always be performed so as not to jeopardize the health of the patient. Such an assay can be performed in about 3-4 minutes, and should not significantly affect the stability or efficacy of the radiotherapeutic.

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for radiolabeling a chelator-conjugated protein, ligand or peptide with a therapeutic radioisotope for administration to a patient comprising

(i) mixing the chelator-conjugated protein, ligand or peptide with a solution comprising the therapeutic radioisotope or salt thereof, and

(ii) incubating the mixture for a sufficient amount of time under amiable conditions such that a radiolabeled protein, ligand or peptide having ~~sufficient~~ radiochemical purity greater than 95%, ~~and~~ sufficient binding specificity, and ~~having~~ a specific activity of at least about 5 mCi/mg, is achieved such that the radiolabeled protein, ligand or peptide may be administered directly to the patient without further purification.